# US 2016/0250387 A1 · Drug releasing coatings for medical devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250387 A1
- Document ID: US20160250387A1
- Status: Published application
- Kind: A1
- Application number: 15/067,739
- Filed: 2016-03-11
- Published: 2016-09-01
- Earliest claimed: 2006-11-20
- Assignees: Lutonix, Inc.
- Applicants: Lutonix, Inc.
- Inventors: Lixiao Wang
- Web page: https://patentgrep.com/patent/US20160250387A1

## CPC

- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61F 2/844: folded prior to deployment
- A61F 2/958: Inflatable balloons for placing stents or stent-grafts
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61L 29/08: Materials for coatings
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/08: Materials for coatings
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/428: Vitamins, e.g. tocopherol, riboflavin
- A61L 2300/606: Coatings
- A61L 2300/608: having two or more layers
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a coating layer overlying an exterior surface of the medical device, the dried coating layer comprising a hydrophobic therapeutic agent, a first additive, wherein:
the hydrophobic therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof; and
the first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof.

### Claim 15 (depends on 14)

The medical device of claim 14, wherein the coating layer further comprises a second additive selected from the group consisting of sorbitol, sorbitan, xylitol, gluconolactone, and combinations thereof.

### Claim 16 (depends on 15)

The medical device of claim 15, wherein the coating layer further comprises an antioxidant comprising propyl gallate.

### Claim 17 (depends on 15)

The medical device of claim 15, wherein:
the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof.

### Claim 18 (depends on 15)

The medical device of claim 15, wherein:
the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and
the second additive is selected from the group consisting of sorbitol, gluconolactone, and combinations thereof.

### Claim 19 (depends on 15)

The medical device of claim 15, wherein:
the first additive is PEG-20 sorbitan monolaurate or PEG-20 sorbitan monooleate; and
the second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.

### Claim 20 (depends on 14)

The medical device of claim 14, wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.

### Claim 21 (depends on 14)

The medical device of claim 14, wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.

### Claim 22 (depends on 14)

The medical device of claim 14, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

### Claim 23 (depends on 14)

The medical device of claim 14, wherein:
the medical device is a balloon catheter;
the hydrophobic therapeutic agent is paclitaxel; and
the coating layer further comprises an antioxidant comprising propyl gallate.

### Claim 24 (depends on 23)

The medical device of claim 23, wherein the balloon catheter is a cutting balloon catheter or a scoring balloon catheter.

### Claim 25

A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a dried coating layer overlying an exterior surface of the medical device, the dried coating layer comprising a hydrophobic therapeutic agent, and a combination of a water-soluble first additive and a water-soluble second additive, wherein:
the hydrophobic therapeutic agent is chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;
the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and
the water-soluble second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.

### Claim 26 (depends on 25)

The medical device of claim 25, wherein the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles.

### Claim 27 (depends on 25)

The medical device of claim 25, wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is gluconolactone.

### Claim 28 (depends on 25)

The medical device of claim 25, wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is sorbitol or xylitol.

### Claim 29 (depends on 25)

The medical device of claim 25, wherein:
the water-soluble first additive is PEG-20 sorbitan monooleate; and
the water-soluble second additive is gluconolactone.

### Claim 30 (depends on 25)

The medical device of claim 25, wherein:
the water-soluble first additive is PEG-20 sorbitan monooleate; and
the water-soluble second additive is sorbitol or xylitol.

### Claim 31 (depends on 25)

The medical device of claim 25, wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is lactobionic acid.

### Claim 32 (depends on 25)

The medical device of claim 25, further comprising a top layer overlying a surface of the dried coating layer overlying the exterior surface of the medical device to reduce loss of the hydrophobic therapeutic agent during transit through a body to the tissue.

### Claim 33 (depends on 25)

The medical device of claim 25, wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.
